DIKUL - logo
E-viri
Recenzirano Odprti dostop
  • An orthopoxvirus-based vacc...
    Haagmans, Bart L.; van den Brand, Judith M. A.; Raj, V. Stalin; Volz, Asisa; Wohlsein, Peter; Smits, Saskia L.; Schipper, Debby; Bestebroer, Theo M.; Okba, Nisreen; Fux, Robert; Bensaid, Albert; Foz, David Solanes; Kuiken, Thijs; Baumgärtner, Wolfgang; Segalés, Joaquim; Sutter, Gerd; Osterhaus, Albert D. M. E.

    Science (American Association for the Advancement of Science), 01/2016, Letnik: 351, Številka: 6268
    Journal Article

    Middle East respiratory syndrome coronavirus (MERS-CoV) infections have led to an ongoing outbreak in humans, which was fueled by multiple zoonotic MERS-CoV introductions from dromedary camels. In addition to the implementation of hygiene measures to limit further camel-to-human and human-to-human transmissions, vaccine-mediated reduction of MERS-CoV spread from the animal reservoir may be envisaged. Here we show that a modified vaccinia virus Ankara (MVA) vaccine expressing the MERS-CoV spike protein confers mucosal immunity in dromedary camels. Compared with results for control animals, we observed a significant reduction of excreted infectious virus and viral RNA transcripts in vaccinated animals upon MERS-CoV challenge. Protection correlated with the presence of serum neutralizing antibodies to MERS-CoV. Induction of MVA-specific antibodies that cross-neutralize camelpox virus would also provide protection against camelpox.